Jounce Therapeutics

About:

Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.

Website: http://www.jouncetx.com

Twitter/X: jouncetx

Top Investors: Wellington Management, Cormorant Asset Management, Foresite Capital, Omega Funds, Casdin Capital

Description:

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Total Funding Amount:

$194M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2013-01-01

Founders:

Drew Pardoll, James P. Allison, Louis M. Weiner, Padmanee Sharma, Robert D. Schreiber, Thomas F. Gajewski

Number of Employees:

101-250

Last Funding Date:

2021-03-10

IPO Status:

Public

Industries:

© 2025 bioDAO.ai